Apimeds Pharmaceuticals and Lokahi Therapeutics Announce FDA Type C Meeting Scheduled for LT-100 (Apitox)
Apimeds Pharmaceuticals US, Inc. (APUS)
Company Research
Source: Business Wire
MATAWAN, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. and Lokahi Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Addiction Medicine and Pain Medicine (DAAP) has confirmed a Type C meeting to discuss LT-100 (Apitox), a non-opioid biologic candidate being developed for the treatment of the signs and symptoms of osteoarthritis (OA). The meeting will be conducted via teleconference on Monday, May 4, 2026.The scheduled interaction follows the recent submission of a Type C meeting request and represents an important step in the coordinated U.S. regulatory strategy for LT-100. The meeting is intended to support alignment with the FDA on key development considerations and the overall path forward for the program in the U.S.LT-100 is pure honeybee venom, with a long history of clinical investigation. The product was originally developed and approved in South Korea, where it was approved for market
Show less
Read more
Impact Snapshot
Event Time:
APUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APUS alerts
High impacting Apimeds Pharmaceuticals US, Inc. news events
Weekly update
A roundup of the hottest topics
APUS
News
- E.F. Hutton Advises on Strategic Merger Between Apimeds and MindWave, Aligning Biotech Growth with AI-Enabled Financial InnovationGlobeNewswire
- Apimeds Pharmaceuticals and MindWave Innovations Announce Closing of $100MM PIPE Financing and Activation of 1,000 Bitcoin to Power AI-Driven Yield Generation StrategyBusiness Wire
APUS
Sec Filings
- 2/27/26 - Form DEFM14C
- 2/17/26 - Form 425
- 2/17/26 - Form 8-K/A
- APUS's page on the SEC website